COOKIE-SETTINGS We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather. Accept all cookies Accept cookies for statistical purposes Accept only necessary cookies (May lead to content and user experience restrictions) Show details Privacy policy Imprint Pharma Diagnostics Our expertise as a pharmaceutical company medac is a future-oriented company and has been growing dynamically since fifty years. More than 1800 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees Job offers Information for patients Find out more about our company, different pathological conditions and possible therapeutic strategies. medac’s product range Information for professionals In this area you can find information about selected indications and about our therapeutic products in the specialist area concerned. Educational material News Previous 01/13/2021 A reliable diagnosis with the new cPass test by medac GmbH Is it possible that I’m already immune to COVID-19? In the time of lockdowns and vaccination chaos, a new diagnostic procedure finally provides... Read more 03/20/2020 medac statement on Coronavirus (SARS-CoV-2) At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply... Read more 07/30/2019 Trecondi® - the new original from medac After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation... Read more Next Warning of the off-label use of BCG-medac for the prevention (vaccination) or treatment of COVID-19 The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information: https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/2020/ablage2020/2020-05-26-warnung-off-label-einsatz-bcg.html?nn=11245740 Events No news available. General Contact medac GmbH Theaterstr. 6 22880 Wedel +49 (0)4103 - 8006-0 contact@medac.de Media Contact medac Pressesprecher Volker Bahr Theaterstraße 6 22880 Wedel +49 (0)4103 – 8006 9111 +49 (0)4103 – 8006 8934 presse@medac.de Imprint Privacy policy General Terms and Conditions of Sale and Delivery Download-Center Reporting of side-effects Last updated on: 02/05/2021. Copyright © 2021 medac GmbH.